TNFSF13 and autoimmune disease: Overall, while both BAFF/APRIL-targeted therapies and BTK inhibitors aim to modulate dysfunctional B cell responses in autoimmune diseases, they operate via distinct mechanisms, exhibit varying clinical efficacies and safety profiles, and may require different approaches in patient management and precision medicine.